| Schedule of Reconciliation to the Consolidated Net Loss |
A reconciliation to
the consolidated net loss for the three and nine months ended September 30, 2025 and 2024 is included at the bottom of the table below.
| |
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Significant segment expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| General and administrative (1) |
|
$ |
1,539,554 |
|
|
$ |
1,117,888 |
|
|
$ |
4,696,702 |
|
|
$ |
4,315,884 |
|
| Pre-clinical research (1) |
|
|
136,271 |
|
|
|
54,779 |
|
|
|
301,607 |
|
|
|
1,281,758 |
|
| CMC (1) |
|
|
293,982 |
|
|
|
355,977 |
|
|
|
617,992 |
|
|
|
1,154,748 |
|
| Clinical development (1) |
|
|
926,228 |
|
|
|
944,954 |
|
|
|
4,289,307 |
|
|
|
2,839,726 |
|
| Depreciation and amortization |
|
|
158,942 |
|
|
|
162,257 |
|
|
|
482,396 |
|
|
|
486,771 |
|
| Share based compensation expense |
|
|
52,987 |
|
|
|
133,882 |
|
|
|
209,190 |
|
|
|
641,311 |
|
| Other segment items (2) |
|
|
2,091 |
|
|
|
234,867 |
|
|
|
3,939 |
|
|
|
270,214 |
|
| Total operating and segment expenses |
|
|
3,110,055 |
|
|
|
3,004,604 |
|
|
|
10,601,133 |
|
|
|
10,990,412 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reconciliation of net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
46,870 |
|
|
|
(70,306 |
) |
|
|
115,301 |
|
|
|
(79,212 |
) |
| Realized foreign currency translation loss from dissolution of subsidiaries |
|
|
- |
|
|
|
- |
|
|
|
(7,171 |
) |
|
|
- |
|
| Foreign currency gain/(loss) |
|
|
(26,250 |
) |
|
|
- |
|
|
|
3,040 |
|
|
|
- |
|
| Other income |
|
|
8,619 |
|
|
|
- |
|
|
|
28,083 |
|
|
|
- |
|
| Interest and dividends, net |
|
|
43,396 |
|
|
|
75,076 |
|
|
|
145,065 |
|
|
|
342,701 |
|
| Segment and consolidated net loss |
|
$ |
3,037,420 |
|
|
$ |
2,999,834 |
|
|
$ |
10,316,815 |
|
|
$ |
10,726,923 |
|
| (1) | includes personnel costs and excludes share-based compensation expense |
| (2) | includes loss from sale of assets, and loss on asset write offs |
|